CharlesdeGiorgio
LIMITED

Direct Healthcare Professional Communication

6th May 2019

Lartruvo® ▼ (olaratumab): revocation of the EU marketing authorisation due to lack of therapeutic efficacy

Dear Healthcare Professional,

Eli Lilly and Company in agreement with the European Medicines Agency (EMA) and the Maltese Medicines Agency (MMA) would like to inform you of the following:

Summary

- **The phase 3 study (ANNOUNCE) of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS) did not confirm the clinical benefit of Lartruvo.**
- **As a consequence, the benefit-risk balance of Lartruvo is not favourable and the marketing authorisation in the EU will be revoked.**
- **No new patients should be started on Lartruvo outside of a clinical trial. For patients currently on treatment with Lartruvo, available treatment options should be considered.**

Background information

Lartruvo was authorised in the European Union in November 2016 to treat advanced soft tissue sarcoma. At time of its approval, data on the effects of Lartruvo were limited due to the small number of patients included in the main study which supported authorisation. The medicine was therefore granted a marketing authorisation on condition that the company provided additional data from the ANNOUNCE study in order to confirm the efficacy and safety of the medicine.

The ANNOUNCE study did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. Specifically, the study did not meet the primary endpoints to prolong survival in the overall population (HR: 1.05; median 20.4 vs. 19.8 months for Lartruvo + doxorubicin and doxorubicin, respectively) or in the leiomyosarcoma (LMS) sub-population (HR: 0.95; Median 21.6 vs. 21.9 months for Lartruvo + doxorubicin and doxorubicin, respectively). There was no clinical benefit in key secondary efficacy endpoints (progression-free survival in the overall population: HR 1.23; median 5.4 months vs. 6.8 months for Lartruvo + doxorubicin and doxorubicin, respectively). No new safety concerns were identified.

As this study did not confirm clinical benefit, the conditional marketing authorisation for Lartruvo will be revoked.

TRIQ IL-KAN. K. PIROTTA, B'KARA, BKR 1114 - MALTA • TEL: (356) 25 600 500 • FAX: (356) 25 600 200
e-mail: admin@charlesdegiorgio.com • www.charlesdegiorgio.com • Vat Reg No: MT11118610
Directors: D. Stellini (Managing), G.Balzan Demajo

CharlesdeGiorgio
LIMITED

Call for reporting

Healthcare professionals and patients are encouraged to report any adverse events in accordance with the national spontaneous reporting system to the MMA:

Online: http://www.medicinesauthority.gov.mt/adrportal

Company contact point

Please do not hesitate to contact Charles de Giorgio Ltd. for further clarification of your questions.

Tel: +356 25600 500

Yours sincerely,

Mark Mallia
Pharma Sales and Marketing Manager
Charles de Giorgio Ltd
p: +356 25 600 805
f: +356 25 600 200 m: +356 99 42 46 21
a: Triq il-Kan. K. Pirotta, B'Kara BKR1114, Malta
w: charlesdegiorgio.com